# Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

> **NCT00963274** · PHASE1 · COMPLETED · sponsor: **Virginia Commonwealth University** · enrollment: 18 (actual)

## Conditions studied

- Leukemia
- Lymphoma

## Interventions

- **DRUG:** Bortezomib
- **DRUG:** Romidepsin

## Key facts

- **NCT ID:** NCT00963274
- **Lead sponsor:** Virginia Commonwealth University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04-26
- **Primary completion:** 2014-07-17
- **Final completion:** 2018-04-13
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2018-04-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00963274

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00963274, "Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT00963274. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*